Description: <b>Brusatol</b> is a quassinoid (highly oxygenated triterpenoid derivative) isolated from Brucea javanica. It is best known in oncology research as a potent functional inhibitor of the Nrf2 pathway, which places it at the center of redox regulation, chemoresistance, and mitochondrial stress in cancer cells.<br>
<br>
<br>
<p><b>Brusatol</b> — brusatol is a naturally occurring quassinoid, a highly oxygenated degraded triterpenoid isolated mainly from <i>Brucea javanica</i>. It is best characterized as a preclinical small-molecule anticancer sensitizer that suppresses stress-response and survival signaling, with the strongest historical association being transient depletion of NRF2-dependent cytoprotective signaling. Its formal classification is a plant-derived natural product and experimental anticancer chemosensitizer. Standard abbreviations include BRU and BT. Mechanistically, current evidence no longer supports treating brusatol as a clean or selective NRF2 inhibitor; rather, NRF2 suppression appears to be one important downstream consequence of broader translational and short-lived protein depletion, with additional context-dependent effects on STAT3, AKT/mTOR, EGFR-linked signaling, EMT/metastasis programs, and ferroptosis susceptibility.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Global translational suppression with preferential depletion of short-lived stress-survival proteins, including NRF2</li>
<li>Functional suppression of the NRF2 antioxidant program with downregulation of HO-1, NQO1, GCLC and related redox-defense outputs</li>
<li>ROS amplification and redox-vulnerability induction, especially in combination settings</li>
<li>Inhibition of survival signaling pathways including STAT3 and, in some models, PI3K/AKT/mTOR</li>
<li>Promotion of mitochondrial apoptosis with caspase activation and Bcl-2-family shift</li>
<li>Anti-invasive and anti-metastatic activity via EMT suppression and reduced MMP/ROCK-associated migratory signaling</li>
<li>Ferroptosis sensitization or induction in selected models through NRF2-system xCT-GSH axis disruption</li>
<li>Chemosensitization and radiosensitization through collapse of adaptive cytoprotective resistance programs</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Native brusatol has meaningful delivery constraints and limited development maturity. Published PK work is mainly preclinical, including intravenous mouse and rat studies, tissue-distribution studies, metabolite identification, and formulation work designed to improve oral exposure. Nanoparticle and self-microemulsifying systems have been explored because practical systemic delivery and therapeutic index remain limiting issues.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many cell studies use submicromolar to low-micromolar concentrations, which may be pharmacologically active but are not yet anchored to a validated human exposure range because there is no established clinical dosing framework. Some mechanistic claims likely reflect concentration- and model-dependent pleiotropy. Combination efficacy appears more translationally relevant than assuming selective single-target inhibition at fixed in-vitro concentrations.</p>
<p><b>Clinical evidence status:</b> Preclinical only. Evidence includes extensive in-vitro work and multiple animal studies showing tumor-growth inhibition and sensitization to chemotherapy or targeted therapy, but no established human oncology efficacy and no identified registered interventional cancer trial establishing clinical use of purified brusatol as an anticancer drug.</p>
<h3>Mechanistic relevance of brusatol in cancer</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Protein translation suppression</td>
<td>↓ short-lived survival proteins</td>
<td>↓ protective proteins</td>
<td>P-R</td>
<td>Upstream cytotoxic driver</td>
<td>Best current high-level interpretation. Explains why NRF2 falls rapidly but also why brusatol affects multiple unrelated pathways; reduces confidence in strict target selectivity.</td>
</tr>
<tr>
<td>2</td>
<td>NRF2 antioxidant program</td>
<td>↓ NRF2, ↓ HO-1, ↓ NQO1, ↓ GCLC</td>
<td>↓ NRF2 defense possible</td>
<td>P-R</td>
<td>Redox-defense collapse</td>
<td>Historically central mechanism and still highly relevant functionally, especially for chemosensitization, but likely not exclusive or fully specific.</td>
</tr>
<tr>
<td>3</td>
<td>Oxidative stress increase</td>
<td>↑ ROS</td>
<td>↑ injury risk (context-dependent)</td>
<td>R-G</td>
<td>Redox crisis and death sensitization</td>
<td>Often emerges after antioxidant-program suppression; especially important in combination with cisplatin, taxanes, trastuzumab, lapatinib, or ferroptosis-linked settings.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial apoptosis</td>
<td>↑ Bad or Bax signaling, ↓ Bcl-2, ↑ caspase-9, ↑ caspase-3</td>
<td>↔ to ↑ toxicity risk</td>
<td>R-G</td>
<td>Execution of tumor cell death</td>
<td>Common endpoint across models. Frequently linked to ROS accumulation and survival-pathway shutdown.</td>
</tr>
<tr>
<td>5</td>
<td>STAT3 and JAK kinase signaling</td>
<td>↓ JAK1/2, ↓ Src, ↓ STAT3, ↓ nuclear STAT3</td>
<td>↔</td>
<td>R-G</td>
<td>Reduced growth, survival, EMT, metastasis</td>
<td>Supported strongly in HNSCC and HCC systems; likely important in subsets where STAT3 is dominant.</td>
</tr>
<tr>
<td>6</td>
<td>PI3K AKT mTOR axis</td>
<td>↓ PI3K, ↓ p-AKT, ↓ mTOR</td>
<td>↔</td>
<td>R-G</td>
<td>Proliferation and survival suppression</td>
<td>Observed in several tumor models; may be partly direct in some contexts and partly secondary to broader stress signaling collapse in others.</td>
</tr>
<tr>
<td>7</td>
<td>EGFR related signaling</td>
<td>↓ EGFR-TK activity, ↓ HER2-AKT-ERK signaling</td>
<td>↔</td>
<td>R-G</td>
<td>Growth inhibition and targeted-therapy sensitization</td>
<td>Evidence includes cell-free EGFR-TK inhibition and combination activity in HER2-positive models. Relevance is plausible but not yet as established as the redox-survival axes.</td>
</tr>
<tr>
<td>8</td>
<td>EMT and metastasis program</td>
<td>↓ EMT, ↓ migration, ↓ invasion, ↓ MMP2, ↓ MMP9, ↓ ROCK1</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic effect</td>
<td>Seen in colorectal, HCC, NSCLC, ESCC and other models. Often downstream of STAT3, AKT, or redox disruption.</td>
</tr>
<tr>
<td>9</td>
<td>Ferroptosis susceptibility</td>
<td>↑ ferroptosis sensitivity, ↓ GSH defense</td>
<td>↔ to ↑ oxidative vulnerability</td>
<td>R-G</td>
<td>Non-apoptotic death facilitation</td>
<td>Growing 2025-2026 literature suggests this is mechanistically relevant in some cancers, but still appears context-dependent rather than universal.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization and radiosensitization</td>
<td>↑ chemo response, ↑ radio response</td>
<td>↔ to ↓ tissue tolerance</td>
<td>G</td>
<td>Resistance reversal</td>
<td>One of the most reproducible translational themes. Benefit likely comes from disabling adaptive antioxidant and pro-survival buffering rather than from a single receptor-like target.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Bioavailability limits, pleiotropy, toxicity interaction risk</td>
<td>Potential collateral stress sensitization</td>
<td>G</td>
<td>Restrains development</td>
<td>No established clinical oncology deployment. Preclinical PK is limited, formulation optimization is still active, and recent work suggests brusatol can worsen cisplatin nephrotoxicity by altering cisplatin pharmacokinetics.</td>
</tr>
</table>
<p>P: 0–30 min</p>
<p>R: 30 min–3 hr</p>
<p>G: >3 hr</p>